IOLYX

Transforming Immuno-Ophthalmology

Our Company

Iolyx Therapeutics is transforming the standard of care for ocular disease at the intersection of immunology and ophthalmology. Utilizing innovative pathways and tailored formulations for precise delivery to relevant tissues, Iolyx products are designed to target ocular inflammation at its source. Our ultimate goal is to develop targeted therapeutics that offer superior efficacy, safety, and convenience compared to traditional steroids and immunosuppressants, which have significant limitations and short and long-term side effects.

Our Focus

Front of The Eye

“Front of the Eye” refers to the ocular surface, the anterior compartment, or the outward-facing part of the eye.   Diseases such as Dry Eye, Ocular Allergies, Rosacea, and Uveitis are incredibly common, particularly in women, and cause significant burden to quality of life. Today, treatments for these diseases typically only target limited mechanisms of inflammation, and can cause discomfort or significant side effects.  Iolyx is developing broad-based immunomodulatory therapies with the hope to provide transformative treatments which are safer, more tolerable, and more convenient than the standard of care today.

Back of The Eye

“Back of the Eye” refers to the inner eye from the lens to the retina to the optic nerve, including the vital layer of cells that send visual signals to the brain.  Reduction of  inflammation plays an important role in retinal health, and diseases such as Age-related Macular Degeneration, Diabetic Retinopathy, and Posterior Uveitis. Today, steroids or agents focused on vascular leakage are used to treat these diseases, with sub-optimal convenience and safety concerns ranging from glaucoma to cataracts. Iolyx aims to create targeted therapies to restore immune homeostasis for those with vision-threatening ocular inflammation in the Back of the Eye.

Sources: Kalangara 2017, Yang 2021, Nichols 2016, Minkus 2021, Husam Al-Ani 2022, Fung 2020, AAO Uveitic Glaucoma 2023, Khiangte 2019, NEI, CDC VEHSS, Bright Focus Foundation

Sources: Kalangara 2017, Yang 2021, Nichols 2016, Minkus 2021, Husam Al-Ani 2022, Fung 2020, AAO Uveitic Glaucoma 2023, Khiangte 2019, NEI, CDC VEHSS, Bright Focus Foundation, WHO Fact Sheet 2023

Our Team

We Put The “EYE” In Team

Elizabeth Jeffords, MBT

CEO & President

Erin Newman

Chief Development Officer

Shannon Dahl, PhD

Chief Scientific Officer

Heather Berger, PhD

Chief Business Officer

Roxane Li

Director of Project Management & Chief of Staff

Richard Graham, PhD

Head of CMC/Formulations

Hovik Gukasyan, PhD

Head of Pharmacology

Rose Verhoeven, MTox

Head of
Non-Clinical/Tox

Houman Hemmati, MD, PhD

Head of Medical

John Snyder

Head of Finance & Accounting

Lisa Tuomi, PharmD

Head of IR, PR, & Medical Communications

Pipeline